BioNTech broadens investor base with $325M B round

While BioNTech remains quiet about a timeline for a potential listing, the German biotech has further broadened its investor base with multiple Asia-Pacific firms backing a $325 million series B round as it invests in pipeline programs and specialized manufacturing. The company’s seven clinical programs are all mRNA-based therapeutics, and it aims to start clinical studies of CAR T and small molecule programs within a year.

Long supported by the Strüngmann family office from its 2008 inception, BioNTech SE added U.S. investors in its $270 million series A round, announced in January 2018. The series B round includes investors based in Asia as well, fulfilling an element of BioNTech’s financial strategy, BioNTech CBO Sean Marett told BioCentury...